Eli Lilly (LLY)

Volatility in the stock market often leads to great long-term opportunities for investors.

I am not turned off by the company's recent setbacks.

Patients taking retatrutide, lost 16.8% of their body weight over 40 weeks.

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based company fell nearly 4% during the session, trading in the range of $211 to $219, a stark contrast to the

Hut 8 operates large-scale data centers supporting Bitcoin mining and high-performance computing for institutional clients.

Eli Lilly shares made a large move lower. But they are oversold and getting close to a level where there may be support.

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from its consolidation ambitions. Instead, strategic buyers have evolved, trading the broad "mega-merger" attempts of the past for targeted,

As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year characterized by regulatory uncertainty and legal skirmishes, the company’s stock staged a breathtaking 50%+ rally in the first two weeks of March. This [...]

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers. Looking ...

Each of these companies could benefit from this high-growth market over time.

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

Today, March 17, 2026, selective tech gains helped lift the Nasdaq even as oil prices and geopolitical tensions stayed elevated.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 6.3% in the afternoon session after investment bank HSBC downgraded the stoc...

You don't have to go all in to profit from AI.

The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday.

Eli Lilly's stock price is based on growth rates that might fall short.

HSBC downgrades Eli Lilly to reduce, citing pricing pressure, rising competition, and overestimated obesity drug market growth expectations.

Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.

Pfizer has reached a turning point.

Eli Lilly's stock is down this year, and its high valuation may be a big reason why.